Loading...
Loading...
AVDL| Name | Value |
|---|---|
| Revenues | 50.0M |
| Cost of Revenue | 6.2M |
| Gross Profit | 43.9M |
| Operating Expense | 44.2M |
| Operating I/L | -0.3M |
| Other Income/Expense | -2.2M |
| Interest Income | 0.0M |
| Pretax | -2.5M |
| Income Tax Expense | 0.1M |
| Net Income/Loss | -2.6M |
Avadel Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing pharmaceutical products. Its lead product candidate, FT218, is a formulation of sodium oxybate undergoing Phase 3 clinical trials for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company generates revenue through the development and potential commercialization of innovative pharmaceutical treatments for sleep disorders, aiming to address unmet medical needs in this therapeutic area.
